Health & function · Evidence Explainer
Cognitive training improved practiced skills—not survival or proven dementia prevention
ACTIVE supports protocol-specific gains in trained abilities and some long-term function measures. Twenty-year mortality was null, while a lower claims-diagnosed dementia estimate appeared only in a nonrandomized booster-completer subgroup that methodologists dispute.
Discovery, counterevidence, claim mapping, identifiers, funding, correction state and prose were reviewed before release.
Evidence box
Three evidence lanes—not one brain-training verdict
- Study type
- Randomized cognitive-training trial with ten- and twenty-year linked follow-ups
- Studied in
- Independent US adults age 65–94 assigned to memory, reasoning, speed-of-processing training or no-contact control
- Participants / sample
- 2,832 randomized; 2,802 in mortality analysis; 2,021 in the claims-linked dementia analysis
- Publication status
- Peer-reviewed primary reports and current registry records; correction status checked August 2, 2026
- Outcome type
- Trained abilities, daily function, all-cause mortality and claims-diagnosed ADRD
- Development stage
- Protocol-specific research interventions; generic games and commercial descendants are not interchangeable
- Conflicts / funding
- NIH support; mortality report declared no conflicts; commercial descriptions are not efficacy evidence
- Our assessment
- Trained-ability benefits and some function signals; no mortality benefit and no reliable randomized dementia-prevention conclusion
- Reporting confidence
- High for trained abilities and null mortality; low for the disputed booster subgroup
Start here
Key takeaways
- Training improved the abilities participants practiced; ten-year persistence was detectable for reasoning and speed, not memory.
- The 20-year analysis found no significant all-cause mortality effect for any training arm.
- The reported HR 0.75 for claims-diagnosed ADRD appeared only among booster-completing speed trainees; randomized arms were null, non-boosters had HR 1.01, and the subgroup analysis is contested.
Keep the outcomes separate
What we know / what we do not know
What we know
- The trial provides protocol-specific randomized evidence for trained abilities and some long-term daily-function measures.
- The long-term mortality analysis directly found no significant survival effect from memory, reasoning or speed training.
What we do not know
- Whether booster completion caused the claims-based dementia difference, because booster completion was not randomized.
- Whether generic brain games or commercial implementations reproduce the studied protocols or prevent dementia.
Evidence at a glance
The answer changes with the outcome.
Rows preserve outcome boundaries; they are not a score, ranking, or recommendation.
| Outcome | Result | Boundary |
|---|---|---|
| Trained ability and function | Memory, reasoning and speed improved initially; reasoning and speed persisted at ten years, with reported function signals. | Practiced-domain performance is not generalized rejuvenation. |
| All-cause mortality | No significant effect for memory, reasoning or speed training. | The trial does not support a lifespan claim. |
| Claims-diagnosed dementia | HR 0.75 only in booster completers; randomized arms null and non-boosters HR 1.01. | Post-randomization, claims-based and methodologically contested. |
The bottom line
ACTIVE has three evidence lanes that must remain separate. Training improved specifically practiced abilities and some long-term function measures. The 20-year mortality analysis found no significant effect on all-cause mortality. A lower claims-diagnosed dementia estimate appeared only in speed trainees who completed boosters—a post-randomization subgroup whose interpretation is contested.
Why this matters
“Brain training works” can refer to doing better on practiced tasks, preserving daily function, preventing dementia, or living longer. Those are different claims. ACTIVE is valuable because its long follow-up shows both where evidence persists and where the stronger story fails.
What researchers did
ACTIVE randomized 2,832 independent adults age 65–94 to memory, reasoning, speed-of-processing training or no-contact control. Some eligible trainees were later offered boosters. Booster completion was not a fresh randomized assignment, so completers and non-completers cannot be assumed comparable.
What they found
At ten years, reasoning and speed—but not memory—retained detectable trained-ability effects. Intervention groups reported less decline in instrumental daily activities, while self-reported and performance-based function remained distinct. In the mortality analysis, 2,021 of 2,802 participants died through 2019; no training arm significantly changed all-cause mortality.
How strong is the evidence?
Randomization supports protocol-specific trained-ability conclusions. Long follow-up strengthens the mortality result. The claims-based dementia analysis is weaker: randomized arm comparisons were null, while HR 0.75 (95% CI 0.59–0.95) appeared only among booster-completing speed trainees; non-booster speed trainees had HR 1.01 (95% CI 0.81–1.27).
What this evidence does not show
ACTIVE does not establish that generic brain games prevent dementia, extend life, or rejuvenate the brain. It does not show that the booster subgroup difference was caused by boosters rather than post-randomization selection or other differences.
Safety, interpretation, and funding
The claims-based dementia paper, published methodological critique and authors’ response belong together. Critics raised comparability, attrition and selection, claims diagnosis, lack of prespecification and multiple unadjusted subgroup comparisons. NIH supported ACTIVE and the long-term work; commercial product descriptions are not independent evidence.
What happens next
A stronger dementia test would preserve randomization, prespecify the clinical endpoint and booster comparison, retain participants, verify diagnoses beyond claims, adjust planned multiplicity and replicate the protocol independently.
Primary sources
Sources, roles and limits
- Ball et al., original ACTIVE randomized report
- Identifier
- PMID:12425704 · DOI:10.1001/jama.288.18.2271 · NCT00298558
- Role
- Primary randomized trained-ability evidence
- Limitation
- Protocol-specific cognitive outcomes; not dementia or survival.
- Rebok et al., ten-year ACTIVE follow-up
- Identifier
- PMID:24417410 · PMCID:PMC4055506 · DOI:10.1111/jgs.12607
- Role
- Long-term ability and function evidence
- Limitation
- Self-reported and performance-based function remain distinct.
- Chen et al., twenty-year mortality analysis
- Identifier
- PMID:39358997 · PMCID:PMC12234222 · DOI:10.1093/aje/kwae381
- Role
- Primary long-term null counterevidence
- Limitation
- Linked follow-up; no significant all-cause mortality effect by training arm.
- ACTIVE claims-based dementia analysis
- Identifier
- PMID:41669119 · PMCID:PMC12884427 · DOI:10.1002/trc2.70197
- Role
- Secondary claims-linked subgroup evidence
- Limitation
- Randomized arms were null; booster completion was not randomized.
- Published methodological critique
- Identifier
- DOI:10.1002/trc2.70280
- Role
- Contradictory methodological assessment
- Limitation
- Raises selection, claims, prespecification and multiplicity concerns.
- Authors’ response to critique
- Identifier
- PMID:42454025 · DOI:10.1002/trc2.70290
- Role
- Response and dispute context
- Limitation
- A response does not resolve the need for randomized replication.
Connected topics
Continue through the knowledge system
Continue with real coverage
Keep reading
These are learning paths, not rankings, recommendations, or evidence that the stories support one another.
Another cognition trial where overall and subgroup results diverge
Hearing intervention did not slow cognitive decline across the full ACHIEVE trial
The three-year trial was null across its full cohort. Signals in higher-risk groups need confirmation and do not establish dementia prevention.
Evidence scopeHuman outcomes · randomized trial with subgroup signals
Small cognitive-test differences without a dementia endpoint
Multivitamins moved some tests and aging clocks. What does that mean?
COSMOS found small cognitive-test differences and modest movement in two DNA-methylation clocks; neither establishes dementia prevention or longer life.
Evidence scopeHuman cognitive tests and biomarkers · correlated randomized substudies
A contrast between function evidence and longevity claims
Exercise has strong evidence for function—not proof of slower biological aging
Human trials support mobility and physical function in defined populations. Lifespan and biological-age claims require separate evidence.
Evidence scopeHuman function · mature randomized evidence
Disclosures and history
- August 2, 2026 — source discovery, verification and counterevidence completed before prose drafting.
- August 2, 2026 — atomic claim map, article draft, identifiers, funding, correction state and inference boundaries reviewed.
- Corrections: none as of publication; ACTIVE’s published methodological dispute is shown in the evidence record.